Here’s what you should know:
1. The European Commission’s probe was in its 16th day as of Oct. 22. The commission is expected to inform Takeda and Shire either formally or informally about the stance of their deal.
2. Both companies expect the deal will earn regulatory approval.
3. Takeda’s $62 billion acquisition will make it one of the world’s largest and most indebted drug makers.
More articles on supply chain:
Optum’s revenues grow to $25.4B in Q3 & more — 8 ASC company key notes
CMS investigating HealthCare.gov data breach affecting 75K individuals
New York ASC partners with payer to deliver region’s 1st outpatient hip replacements
